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Objective. To evaluate outcomes of cultivated limbal epithelial transplantation (CLET) formanagement of ocular surface failure due
to limbal stem cell deficiency (LSCD). Design. Prospective, noncomparative, interventional case series and extensive comparison
with recent similar studies. Participants. Twenty eyes with LSCD underwent CLET (11 autologous; 9 allogeneic) and were followed
up for 3 years. Etiologies were divided into 3 prognostic categories: Group 1, chemical injuries (7 eyes); Group 2, immune-based
inflammation (4 eyes); and Group 3, noninflammatory diseases (9 eyes). Intervention. Autologous and allogeneic limbal epithelial
cells were cultivated on amnioticmembranes and transplanted. Evaluationswere based on clinical parameters, survival analysis, and
in vivo confocal microscopy (IVCM). European Union Tissues/Cells Directive and goodmanufacturing procedures were followed.
Main Outcome Measures. Improved clinical parameters, absence of epithelial defects, and improved central corneal epithelial
phenotype. Results. Success rate was 80% at 1-2 years and 75% at 3 years. Autografts and allografts had similar survival. Success
rate was significantly lower in prognostic Group 1 (42.9%) than in Groups 2-3 (100% each). All clinical parameters improved
substantially. By IVCM, 80% of cases improved in epithelial status. Conclusions. CLET improved corneal epithelium quality, with
subsequent improvement in symptoms, quality of life, and vision. These results confirm that CLET is a valid therapy for ocular
surface failure.
1. Introduction
Corneal epithelial stem cells reside throughout the entire
circumference of the corneoscleral limbal niche that includes
the limbal crypts of the palisades ofVogt.They are responsible
for the maintenance of a healthy corneal epithelium, in part,
by replacing aged or damaged epithelial cells during normal
cell turnover [1–3]. A deficiency or lack of corneal epithelium
renewal due to limbal epithelial stem cell depletion or
dysfunction results in the so-called limbal stemcell deficiency
(LSCD) syndrome, which is a difficult and complex disorder
tomanagewhen it is complete and severe.The hallmark of the
LSCD phenotypic endpoint is the replacement of the corneal
epithelium by conjunctival epithelium. With the loss of the
limbal epithelial stem cells, the limbal conjunctival epithelial
cells invade the superficial cornea. In LSCD, the unstable
ocular surface causes recurrent corneal epithelial breakdown
or nonhealing ulceration and vascularization associated with
chronic inflammation. These surface alterations result in
pain, photophobia, decreased vision, and eventual corneal
blindness [1, 4–10]. This syndrome engenders a high risk for
corneal graft failure as the donor graft (or artificial cornea)
does not have epithelial limbal cells. Likewise, amniotic
membrane transplantation, although useful in partial LSCD
cases, is inadequate for total LSCD, requiring the addition of
limbal tissue [11].
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Logically, the definitive treatment for medically irre-
versible total and/or severe LSCD is the transplantation of
limbal tissue or limbal epithelial cells. This approach repeat-
edly has been shown to help ocular surface regeneration,
and consequently it improves the prognosis of a subsequent
corneal graft [1, 4–10].
Other types of cells are being tested at present and some
have reached the human clinic. For instance, the use of
autologous conjunctival cells cultivated ex vivo on amni-
otic membrane has been recently published [12]. Nonoc-
ular mucosal epithelial cells such as those from the oral
mucosa have provided non-stem cells resources for use in
humans [13, 14], and there are ongoing clinical trials with
this approach. Stem cells derived from nonocular mucosal
or nonepithelial sources have not yet reached the human
clinic, although there are clinical trials already registered
on the potential use of mesenchymal stem cells in LSCD
(https://www.ClinicalTrials.gov/ Identifier: NCT01562002).
Finally, the exciting possibility of using induced pluripotent
stem cells as a source of limbal epithelial stem cells with
translational potential has just begun [15].
The encouragement for limbal epithelial transplantation
was initiated with whole limbal transplantation, first per-
formed in the treatment of severe unilateral ocular surface
disease due to LSCD in 1989 by Kenyon and Tseng [16]. At
present, whole limbal transplantation is performed through a
limbal biopsy, usually of the 4–6 o’clock hour region from the
healthy eye in unilateral LSCD cases [17]. In cases of bilateral
LSCD, limbal transplant tissue is usually derived from a living
relative or a cadaveric donor. At present, these procedures are
performed mainly in the United States of America (USA).
The so-called “Cincinnati procedure” combines conjunctival
limbal allograft and keratolimbal allograft from a living
relative of the patient or the same modified technique in
which tissues are autologous [18].
A novel surgical technique for unilateral LSCD was
recently published by Sangwan et al. [19]. This technique,
called “simple limbal epithelial transplantation,” extracts a
small autologous biopsy of whole limbal tissue from the
contralateral healthy eye. The biopsy tissue is divided into 8–
10 pieces, placed on top of fresh human amniotic membrane
already glued by fibrin to the scraped corneal bed in the
diseased eye. A modification of this technique has just been
published to make this procedure available in the USA by
using cryopreserved amniotic membrane (American Food
and Drug Administration [FDA] approved) in a double layer
that sandwiches the limbal cells [20].
An alternative to whole limbal tissue transplantation is to
use stem cell therapy, where stem cells and other cells resident
in the niches are isolated and expanded. For corneal epithe-
lium reconstruction, the technique is called “cultivated limbal
epithelial transplantation” (CLET), first reported successful
in two cases by Pellegrini et al. in 1997 [21]. In this procedure,
the donor limbal tissue is cultivated in vitro, allowing the
cells to proliferate. The required amount of tissue is fairly
small (1-2 × 1-2mm limbal biopsy), which decreases the risk
of LSCD in the donor eye in unilateral cases. It also makes
it possible, at least in theory, to remove the small biopsy
even if the contralateral donor eye has some limbal damage.
When the disease is bilateral and the LSCD is complete,
the transplant must be allogeneic. Because the source of the
expanded cadaveric tissue can be small and the cultured lim-
bal stem cells may have unique immunoprotective properties
[3, 22], patients subjected to CLET require lower doses of
immunosuppressive therapy for a shorter period of time than
those undergoing whole limbal transplantation.
Currently it is not clear if autologous and allogeneic CLET
have similar success rates. There are also very few reports
that compare CLETwith other means of transplanting limbal
tissues. The only report comparing CLET with whole donor
limbal transplantation suggests that CLET is superior to
conventional techniques [23]. These data are based on each
procedure being performed separately on each eye of the
same patient. Currently there are no studies that compare
CLET with simple limbal epithelial transplantation.
Since that first report in 1997 [21], the long-term restora-
tion capacity of the ocular surface by CLET has been
demonstrated in many reports, and it is more widely used
at present. The CLET procedure is now approved in the
European Union (EU), provided that it follows the EU
Tissues and Cells Directive regarding good manufacturing
procedures (GMP). Further, each transplantation medical
institution must receive permission from each national reg-
ulatory agency. In the USA, there is no FDA approval for the
use of GMP facilities to process and cultivate the autologous
or allogeneic pieces of limbus. Consequently, there are not
many reports on the long-term efficacy of CLET procedures
that follow the most stringent regulations and GMP that, at
least in the EU, equate cell therapy to any other drug therapy.
We report herein the long-term outcome of both autol-
ogous and allogeneic stem cell therapy by CLET. The study
was performed in compliance with the EU Tissues and
Cells Directive for reestablishing the corneal epithelium
phenotype in cases of ocular surface failure due to total or
severe LSCD caused by three groups of diseases: chemical
injuries, immune-based inflammation, and other less severe
diseases. As there are few studies published following these
requirements we have extensively compared our results with
others using similar approaches.
2. Methods
2.1. Patients. Twenty eyes of 19 Caucasian patients diag-
nosed with LSCD were treated by CLET (Table 1). The
protocol was approved by the institutional review board
of IOBA-University of Valladolid. Additional approval was
obtained from theUniversity of Valladolid Ethics Committee.
Informed consent was granted by all patients after full
explanation of all procedures. All experiments and proce-
dures were conducted in accordance with the GMP and
good clinical practice norms and the EU Tissues and Cells
Directive. The Declaration of Helsinki and the provisions
of “National Organic Law 15/1999 of 13 December on the
Protection of Personal Data” (BOE number 298, 14-12-1999,
pp. 43088–43099) were followed in terms of patient rights,
identification, data management, and statistical analysis. As
this study was not a clinical trial but rather a clinical series
study, it was not registered in the clinical trial databases.
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However we have now registered a clinical trial that has just
finished recruitment (https://www.clinicaltrials.gov/).
LSCDdiagnosis was confirmed at the initial visit based on
(1) clinical signs under slit lamp examination (SLE), including
absence of the normal appearance of the limbal area and
at least 3 of the following corneal signs: central epithelial
irregularity ≥2 (range 0–3), central epithelial opacity ≥2
(range 0–4), superficial neovascularization (area and length
of neovessels) ≥3 (range 0–4), and recurrent or persistent
epithelial breakdown, all as defined below; (2) conjunctival-
like or mixed epithelial cell phenotype in the central cornea
(as defined below) observed by in vivo confocal microscopy
(IVCM). All patients had already been through medical
therapies intended to quiet their ocular surface and reverse
as much as possible any treatable limbal dysfunction.
Grading of LSCD was made by clinical evaluation based
on parameters previously published [24, 25]. We selected
only patients with total LSCD, in which the cornea was
completely vascularized and opacified, or severe LSCD, in
which there were recurrent or persistent epithelial defects,
peripheral corneal conjunctivalization involving more than 2
quadrants, and central cornea opacification. Moderate cases
of LSCDwith sectorial conjunctivalization involving less than
2 quadrants, none of which reached the central cornea, were
not considered for this study.
The final outcome of CLET strongly depends on the
etiology of LSCD, among other factors. Thus, the candidate
eyes were grouped into one of the following three etio-
logical categories at the initial visit: Group 1 had chemical
injuries (only included at a minimum of 12 months after the
acute trauma and after other therapies had failed); Group 2
had immune-based inflammatory diseases (i.e., cicatrizing
conjunctivitis such as Stevens-Johnson syndrome, mucous
membrane pemphigoid, atopic keratoconjunctivitis, rosacea-
related keratoconjunctivitis); and Group 3 had other nonin-
flammatory conditions such as sequelae from multiple surg-
eries, chronic sequelae of infectious keratitis already sterile,
congenital aniridia, contact lens wear-related, and so forth.
Although limbal stem cells may have immunosuppressive
properties [3, 22], immune rejection has been reported after
allogeneic CLET [26]. Thus, to prevent any possible immune
rejection, patients who were to receive allogeneic CLET
were started at the initial visit on oral immunosuppressive
therapy with one of the following drugs: 1.5–2.0 g/day of
mycophenolate mofetil, 3–5mg/kg/day of cyclosporine A,
or 1-2mg/kg/day of azathioprine. The immunosuppressive
treatment was maintained for 12 months after CLET, after
which the drug was tapered and discontinued in the next
3 months. We closely monitored potential side effects at
each visit, by phone if necessary and by blood pressure and
blood/urine workup every 1-2 months.
Five to 7 days after the initial visit, unilateral LSCD cases
who agreed to undergo autologous CLET underwent a limbal
biopsy in the contralateral healthy eye. The limbal cells were
grown in culture for 3–5 weeks, and the CLET procedure was
then performed using the harvested cells. Bilateral cases had
allogeneic CLET from cadaveric donors between 4–6 weeks
after the initial visit so that the elapsed times between that
visit and CLET were similar in all patients.
Patients were then evaluated 24 hr. after CLET, weekly for
the first month, monthly until the sixth month, and every
other month up to the first year. After the first year, patients
were evaluated clinically every 6 months for 2 more years,
reporting clinical and photographic outcomes up to three
years after CLET.
Prior to the initiation of these procedures, all patients
were screened for the mandatory transmittable diseases:
human immunodeficiency virus, human T-cell leukemia-
lymphoma virus, hepatitis C and B virus, and syphilis. All
allogeneic tissue donors (cadaveric limbus and human amni-
otic membrane) were similarly screened.
2.2. Cultivation and In Vitro Expansion of Limbal Epithelial
Cells. Cells destined forCLETwere cultured at theUniversity
of Valladolid Institute of Molecular Biology and Genetics
Cell Processing Unit that was licensed and accredited by
the Spanish Agency of Medicines and Sanitary Products
(AEMPS).The institute operates under GMP regulations and
holds a protocol registered as PEI 09-137 by the AEMPS.
Donor human amnioticmembranes and cadaveric limbal
rings came from a registered and accredited tissue bank
(Blood and Tissue Community Center, Oviedo, Asturias,
Spain) and were screened for transmittable diseases as
described above. Allogeneic limbal rings were obtained
within 7 days of death from corneal donors who were under
60 years old. Autologous limbal biopsies were marked by the
surgeon with a stitch in the upper right corner to ensure
consistency when plating the explant to ensure the same
way up; they were sent from the operating room to the cell
production unit at 4–10∘C in culture medium (Figure 1).
Human amniotic membranes were prepared using our
standardized protocol. After thawing the membranes pre-
viously stored at −80∘C, they were washed with phosphate
buffered saline (PBS) (Life Technologies-Gibco, Madrid,
Spain) and treatedwith trypsin (Life Technologies-Gibco) for
15min at room temperature. This was followed by gentle cell
scraping to separate the epithelial cells from the underlying
stroma. Once deepithelialization was complete, the amniotic
membrane stroma was washed twice in PBS to remove cellu-
lar debris. It was then attached to the bottom of a 35mm cell
culture dish so that the basement membrane faced upwards
to serve as a substratum for the limbal epithelial cells.
Limbal tissues were processed during the 4 hr. following
arrival (Figure 1). Either the autologous limbal explant or one
piece of allogeneic limbal tissue (2× 2mm each) was cultured
on top of the denuded amniotic membrane. The culture was
performed initially under a drop of fetal bovine serum (FBS)
(Life Technologies-Gibco), in standard conditions of 37∘C,
95% humidified air/5% CO
2
gas mixture. After 24 hr., 3mL
of the following culture medium was added: DMEM/F12
media (1 : 1 mixture) (Life Technologies-Gibco), 5% FBS
(Life Technologies-Gibco), 50𝜇g/mL hydrocortisone (Sigma
Aldrich, St Louis, MO, USA), 0.5 ng/mL cholera toxin (Gen-
taur, Kampenhout, Belgium), 5 ng/mL insulin-transferrin-
selenium (ITS) (Sigma Aldrich), 0.5% dimethyl sulfoxide
(Sigma Aldrich), 2.5 ng/mL human epidermal growth fac-
tor (Life Technologies-Gibco), and 0.5mg/mL gentamicin
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Figure 1: Limbal biopsy, limbal epithelial cultivation, and cultivated limbal epithelial transplantation (CLET). (a) Healthy donor eye 24 hr.
after a 2 × 2mm limbal biopsy; (b) the biopsy tissue was placed in an Eppendorf tube with culture medium (b1); (c) the biopsy was processed
in a good manufacturing practice-cell processing unit within the next 4 hr. and for the next 4-5 weeks; and (d) the explant was placed on
denuded human amniotic membrane, as viewed by contrast phase microscopy. Limbal epithelial cells began outgrowth from the explant
at 1-2 weeks (d1). The explant was then removed, and the outgrowth was maintained until reaching confluence at which time it contained
approximately 250,000 cells. The cell product was then sent to the medical center for CLET (d2). (e) Superficial keratectomy in the diseased
contralateral eye (Case 1); (e1) human amniotic membrane with epithelial limbal cells confluent on top is removed from culture dish; (e2) the
complex of amniotic membrane-limbal stem cells is placed on top of the previously denuded corneal and sclerolimbal surface; the amniotic
membrane limit is observed (black arrow) with cells facing down and sutured (white arrows). A scleral lens is then applied.
(Life Technologies-Gibco).The culture mediumwas changed
every 3 days.
Limbal explants were kept in culture until a cellular
outgrowth front of approximately 2mm was present (1-2
weeks), and then the explants were removed to avoid stromal
cell contamination and to allow further cell proliferation in
the area previously occupied by the explant, as previously
described [27]. Intermediate and final culture media were
checked for sterility. The final product had to be negative for
the tested microbiologic agents (aerobes, anaerobes, fungi,
and mycobacteria) by using a validated test (Bact-ALERT)
that inactivates antibiotics and thus eliminates the possibility
of masked contamination. Additionally the final product
had to be up to 80% confluent, which meant an average
of 250,000 cells per product. All of these procedures, as
well as the characterization of the cultures, were previously
established in our regular cell culture laboratory [27] and then
transferred to the GMP clean room. Further characterization
of the cultures was not possible due to the scarceness of the
tissues because of the limited amount of biopsy material.
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When cultivated cells were ready for CLET, the final cellular
products were sent to the medical institution within 4 hr. of
the surgery (Figure 1).
For limbal cells grown out of cadaveric explants, an
additional culture was plated outside the GMP facility in
parallel to the one planned for clinical use. In all cases, most
cells (>70%) were highly positive for the limbal progenitor
cell phenotype markers p63, CK15 and weakly positive for
the corneal differentiated epithelium phenotype markers
cytokeratins CK3/CK12 (data not shown). More in depth
staining and complete characterizations were achieved before
transferring this technique from the cell culture lab to the
GMP clean room and thus not repeated [27, 28].
2.3. Surgical Procedures: Limbal Biopsy and CLET. All opera-
tions were performed by the same surgeon (coauthor Jose´ M.
Herreras) and were carried out in a standard manner. Limbal
biopsies were performed under topical anesthesia: 0.1% tetra-
caine chlorohydrate and 0.4% oxybuprocaine chlorohydrate
solution (Colircus´ı Aneste´sico Doble, Alcon Laboratories,
Ft. Worth, TX, USA), following the standards for aseptic
procedures. Biopsies measuring 2 × 2mm were obtained
from regions of the corneoscleral limbus (Figure 1) where the
palisades of Vogt were better defined by SLE and by IVCM at
the initial visit [29].
For the CLET procedure, retrobulbar anesthesia was
achieved with 3 cc of 5% lidocaine (Lidocaine Braun, Braun
Medical SA, Melsungen, Germany). First, a conjunctival
peritomy was performed and tissues were recessed leaving
bare sclera. Fibrovascular pannus, if present, was scraped and
removed from the recipient cornea extending to the limbal
area, allowing a gentle 360∘ limbal peritomy to be performed.
The scraped surface was polished with a diamond bur, and
bleeding vessels were cauterized. Then the CLET graft was
carefully lifted from the culture dish and placed with the
epithelial limbal cells facing the recipient ocular surface so
that cells were in immediate and close contact with the tissues
(cornea and limbal areas) to be repaired. The graft was then
sutured to the perilimbal episclera, 2–4mm posterior to the
limbus, with 8 interrupted 10-0 nylon stitches (Figure 1).
Topical eyedrops (see below) were then applied and an 18–
22mm diameter bandage contact lens was set in place, and
the eye was patched for 24 hr.
Twenty-four hours after surgery, each patient was eval-
uated and topical treatment with the fixed combination of
1% prednisolone acetate and 0.3% tobramycin (Tobradex,
Alcon Laboratories) was prescribed 4 times per day for
6 weeks. Then, 1mg/mL dexamethasone (Maxidex, Alcon
Laboratories) was instilled 4 times a day and slowly tapered
in the next 3 months. The contact lens was removed after
complete disappearance of the amniotic membrane at 2 to 8
weeks, and the stitches were also removed at that time.
2.4. Evaluation Endpoints. Table 1 shows the summary of all
evaluation endpoints performed at the initial visit and at 12
months for each of the 20 eyes subjected to CLET. At 24 and
36 months, only clinical evaluations were performed.
2.4.1. Clinical Examination and Photographs. LSCD-related
symptoms and the impact on each patient’s life were evaluated
with two self-administered questionnaires at the initial visit
and 12months after CLET. First, ocular surface-related symp-
toms caused by LSCD were evaluated with the ocular surface
disease index (OSDI), where scores >12 indicate abnormal
symptomatology, with >32 meaning severe symptoms [30].
Visual function-related aspects of the quality of life were
evaluated with The National Eye Institute 25-Item Visual
Function Questionnaire (NEI-VFQ-25) where higher scores
on a scale 0 to 100 indicate better function [31].
Best corrected visual acuity (BCVA)was determinedwith
a Snellen visual chart. Counting fingers, hand motion, light
perception, and no light perceptionwere converted to Snellen
equivalents, 0.01, 0.001, 0.0001, and 0.00001, respectively, as
published so that a mean value could be calculated [32]. One
or more line changes in BCVA at 12 months after CLET were
considered as improvement or worsening. However, BCVA
improvement is never the primary goal of CLET, as this
technique intends to reconstruct the corneal epithelium and
will not necessarily affect stromal or endothelial pathologies
for which other visual rehabilitation techniques may be
needed after CLET. To avoidmisinterpretation by the patient,
the potential dependence of the visual prognosis on the
surgical procedures (Table 2) judged to be necessary to restore
vision after CLET was explained at the initial visit.
SLE (Topcon SL-8Z, Topcon Corp., Tokyo, Japan) with
fluorescein corneal staining and photographs of the graft-
treated eye were performed at each visit. In autografts, the
biopsy site was alsomonitored. Two of the authors (Beatriz E.
Ramı´rez and Margarita Calonge) evaluated the same param-
eters of LSCD independently, and in case of disagreement,
the average score was recorded. Photographs were taken with
diffuse light using the program IMAGENet (Fuji Fujifilm
Finepix S1 Pro, Fuji Photo Film Co., Ltd., Tokyo, Japan). The
following clinical characteristics were evaluated (Table 3):
ciliary hyperemia, central corneal epithelial opacity, central
corneal epithelial irregularity, corneal epithelial integrity
including superficial punctate keratitis and persistent epithe-
lial defects, and corneal superficial neovascularization based
on the extension or area involved and neovessel length.
2.4.2. In Vivo Confocal Microscopy. IVCM examination of
the central cornea with the Heidelberg Retinal Tomograph
HRT-3 and Rostock Cornea Module (HRT3, Heidelberg
Engineering GmbH, Heidelberg, Germany) was performed
at the initial visit and at 12 months after CLET to evaluate
the phenotype of the epithelium covering the central cornea.
Optical sections from the central cornea were taken at the
basal and superficial layers of the epithelium. Basal cell
morphology was classified as “corneal-like,” having regular,
hexagonal cells with a cell diameter <20𝜇m, or “conjunctival-
like,” having closely packed round or irregularly shaped cells
with a cell diameter of >20𝜇m and occasional goblet cells.
In some cases, the basal cell morphology was classified as
“mixed,” with both phenotypes present [24, 33].
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Table 2: Prognostic classification on the potential for visual recovery in patients suffering from limbal stem cell deficiency and scheduled for
cultivated limbal epithelial transplantation (CLET).
Visual
prognosis Ocular media opacity
Surgeries judged to be necessary to recover full
potential vision
Grade 1 Corneal opacity restricted to anterior cornea (epithelialand anterior stroma) One surgical procedure: CLET only
Grade 2
Corneal opacity restricted to anterior cornea (as Grade
1) plus another noncorneal reason for visual loss (e.g.,
cataract)
Two surgical procedures: CLET+ noncorneal surgery
(e.g., cataract removal most likely)
Grade 3 Full thickness corneal opacity Two surgical procedures: CLET+ corneal transplant
Grade 4 Full thickness corneal opacity plus another noncornealreason for visual loss (e.g., cataract)
Three surgical procedures: CLET+ corneal
transplantation-corneal surgery (e.g., cataract removal)
Grade 0
Any grade of corneal opacity plus noncorneal
irreversible visual loss (e.g., irreversible retinal
pathology, advanced glaucoma)
No potential for gain: CLET performed to avoid globe
removal
IVCM was also performed in the limbal area to select the
site for biopsy in cases of autologous CLET. The area where
more and better defined palisades of Vogt were found was
selected as the site for biopsy. In some cases, the wounding
and healing of the biopsy site were closely followed, as
published elsewhere [29].
2.4.3. Definition of an Overall Success, Partial Success, and
Failure. As visual acuity by itself is a poor endpoint to eval-
uate the success of CLET and associated therapies, we made
an integral evaluation of each patient through primary and
secondary outcomes. Each patient was evaluated with this
same protocol at 12 months after CLET.
Primary outcomes were as follows: (1) improvement in
visual-related aspects of the quality of life evaluated with the
NEI-VFQ-25 or improvement in ocular surface symptoms,
evaluated by OSDI; (2) improvement by at least one step in
at least 3 of the 4 following clinical parameters evaluated by
SLE: ciliary hyperemia, central corneal epithelial irregularity,
central corneal epithelial opacity, and superficial punctate
keratitis; (3) complete absence (Grade 0) of persistent epithe-
lial defects; and (4) presence of amore corneal-like phenotype
in the central cornea as assessed by a change from the
conjunctival phenotype to either corneal ormixed phenotype
or from a mixed phenotype to a corneal phenotype as
evaluated by IVCM [24, 33].
Secondary outcomes were as follows: (1) BCVA improve-
ment of one line ormore and (2) ameliorationmeasured by at
least a one-step decrease in the superficial corneal peripheral
neovascularization area or neovessel length.
The outcome was considered successful only when all
four primary outcomes were achieved. The outcome was
considered partially successful when the patient presented
only two of the primary outcomes or when one primary
outcome in addition to one secondary outcomewas achieved.
Failure meant that only one or none of the primary outcomes
were met.
After the first year, patients were evaluated only clinically
by SLE every 6 months, until the end of follow-up, 3 years
after CLET.
2.5. Statistical Analysis. Quantitative characteristics were
expressed as means ± standard deviations (SD), and quali-
tative variables were described in percentages. The median
and interquartile ranges (IQR) were used to summarize
distributions of ordinal variables. Normality assumptions
were checked by the Shapiro-Wilk test.TheWilcoxon signed-
rank test was used to evaluate improvement of the subjective
questionnaires OSDI and NEI-VFQ-25 and the change in
quantitative and ordinal clinical variables at 12 months after
CLET. Differences between the means of two independent
groups were tested by Student’s 𝑡-test or the nonparametric
alternative, Mann-Whitney 𝑈 test, if the normality assump-
tion was not valid. Relationships between two qualitative
variables were evaluated by Fisher’s exact test. To compare
the success rates for the three predefined prognostic groups
and the type of CLET, the test for equality of proportions was
used. Kaplan-Meier survival analysis was applied to estimate
transplant survival.The log-rank test was used to compare the
univariate survival curves of autologous and allogeneic type.
Statistical analysis was performed using R Statistical Software
version 3.1.0 (Foundation for Statistical Computing, Vienna,
Austria) by a licensed statistician (coauthor IF).
3. Results
The demographic data and initial and final clinical data
collected at 12 months for each case are presented in Table 1.
CLET was performed in 20 eyes (12 males, 8 females) of 19
patients (age, 51.6 ± 14.5 years; range, 27–79 years).There was
no significant difference in age between males and females
(𝑡-test, 𝑝 = 0.3039). All cases were followed up to 3 years,
although follow-up of Case 1 logically ended when he had a
second CLET at month 13 (Table 1).
The three prognostic groups had the following etiologies:
Group 1, composed of chemical injuries, had 7 eyes (35%
of cases, 4 autografts, 3 allografts); Group 2, composed of
immune-based inflammatory diseases, had 4 eyes (20%, 3
with Stevens-Johnson syndrome, 1 with mucous membrane
pemphigoid, all allografts); and Group 3, composed of non-
inflammatory diseases, had 9 eyes (45%, 4 with sequelae from
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multiple surgeries, 3 with postinfectious keratitis, and 2 with
congenital aniridia; 7 autografts, 2 allografts). Twelve eyes
had total LSCD and 8 had severe LSCD. The time between
disease onset and CLETwas 77.2 ± 88.9 months (range, 6–321
months).
The time required for limbal cell expansion and culti-
vation on human amniotic membrane was 24.7 ± 5.8 days.
Cultures from a cadaveric source required 26.1 ± 6.0 days,
and cultures from an autologous source required 23.5 ± 5.7
days; however, this difference was not statistically significant
(𝑡-test, 𝑝 = 0.4251).
Eleven eyes (55%) with unilateral disease had autologous
CLET. Four cases belonged to prognostic Group 1, and 7
cases were in Group 3. The remaining 9 eyes (45%) received
allografts: 3 eyes in Group 1, 4 eyes in Group 2, and 2 eyes
in Group 3 (Table 2). There was no significant difference
in the ages of the autologous and allogeneic recipients (𝑡-
test, 𝑝 = 0.4929) or gender distribution (Fisher’s exact test,
𝑝 = 0.3618). Of the 9 eyes that received allogeneic CLET,
two had unilateral disease. Case 18 had unilateral chemical
injury but also had bilateral perennial allergic conjunctivitis,
and for this reason we did not use her contralateral eye as
donor. Another allograft with unilateral disease was Case 16,
who like Case 1 had unilateral chemical injury. He initially
received an autologous CLET; however, after the 12-month
mandatory follow-up, he received an allogeneic CLET so as
not to compromise the healthy eye with a second biopsy.
Four eyes in Group 2 had allografts (immune-based diseases
are always bilateral) and most cases in Group 3 (7 of 9)
had autografts.Thus there was no independence between the
source of transplanted cells (autografts versus allografts) and
the etiology of the disease (Fisher’s exact test, 𝑝 = 0.0468).
There were no intraoperative or postoperative complica-
tions during either biopsy harvesting or CLET.No episodes of
immune rejection were recorded in the eyes that had received
allografts. All biopsies were extracted from the superior
limbal area as the palisades of Vogt in this area are the richest
source of limbal stem cells [2, 5, 8, 29].
Oral immunosuppression was used in all 9 allograft
patients because immune rejection has been reported to
occur in 23.8% of cases in a series of allogeneic CLET who
were nonimmunosuppressed even though the patients were
given high doses of systemic steroids [26]. Mycophenolate
mofetil (1.5–2 g/day) was used in Cases 5 and 6; cyclosporine
A (3–5mg/kg/day) was prescribed inCases 9, 10, 16, 17, and 18;
and azathioprine (1.5–2mg/kg/day) was used in Cases 15 and
19. The drugs were well tolerated in all cases, and no with-
drawals or discontinuations were necessary. Mycophenolate
mofetil had to be lowered from 2 g/day to 1.5 g/day in Case 5
due to asthenia; cyclosporine A was also lowered from 5 to
3mg/kg/day in Cases 17 and 18 due to mild elevation in blood
pressure. There were no episodes of graft rejection.
There was one adverse event. Case 1 developed a severe
infectious conjunctivitis (Staphylococcus aureus, culture pos-
itive) 9 weeks after surgery. Although the infectious pro-
cess was successfully controlled with topical antibiotics, the
autograft started to deteriorate and was considered a failure
at month 3. Due to the nature of this patient’s job, we had
recommended to him that he take extreme eye protective
measures. He was noncompliant in this recommendation,
which created a risk factor that probably resulted in the eye
infection.
3.1. Overall Success/Failure Rate and Survival Analysis. The
overall success was 80% after both the one- and two-year
follow-up periods. The rate decreased to 75% after 3 years.
At 12 months after CLET, when we performed a thorough
evaluation, 16 of the 20 eyes achieved the four primary
outcomes (Table 1) while 4 eyes (20%, 3 complete failures,
1 partial success) were considered failures. All failures were
from Group 1 (chemical injuries). At one year, the success
rate was clearly lower in prognostic Group 1 (4 out of 7
eyes, 42.9%) than in Groups 2 and 3 (100%). Among these
failures, Case 1 had autologous CLET, and Cases 16, 17, and
18 had allogeneic CLET. Therefore the success rate at one
year for autografts was 90.9% (10 of 11), and for allografts it
was 66.7% (6 of 9). There was no significant difference in the
success/failure rates between the autologous and allogeneic
CLET procedures (equality of proportions, 𝑝 = 0.4315)
(Figure 2).
Even in the failed Cases 1, 17, and 18, there was subjective
improvement as shown by lower OSDI scores and higher
NEI-VFQ-25 scores (Table 1). Case 1 had another CLET (Case
16) in which the final outcomewas graded as a partial success.
This patient elected not to try to rehabilitate his chemi-
cally injured right eye any further as he remained mostly
asymptomatic, and his left eye had full vision. Failed Case 17
(Figure 3) also chose not to do any additional procedure.
Case 18 failed after 9 months. After completing the 3-
year follow-up, she entered a clinical trial on cell therapy
that has finished recruitment (https://www.clinicaltrials.gov/
Identifier: NCT01562002).
All 3 failures and the partial failure after 12 months
belonged to prognostic etiology Group 1. The success rate of
this group, 42.9%, was significantly lower than for Group 2,
the autoimmune-based cases (100% success, equality of pro-
portions, 𝑝 = 0.0096), or Group 3, the miscellaneous group
(100% success, equality of proportions, 𝑝 = 0.0096). None of
the 3 failed cases in Group 1 deteriorated any further after the
CLET failure.
Only one eye failed after the first year (month 35) after
CLET (Case 5, Stevens-Johnson syndrome, prognostic Group
2), showing recurrence of epithelial barrier breakdown. This
patient was also recruited at month 37 for the cell therapy
clinical trial mentioned above.
Survival curve analysis (Figure 2) showed a probability
of success (Kaplan-Meier) at 1 year and 3 years after CLET
of 0.80 (confidence interval [CI] 95%, 0.643–0.996) and 0.75
(CI 95%, 0.582–0.966), respectively, for all cases. Autologous
CLET had the same survival probability, 0.9091 (CI 95%,
0.0867–0.7541), after both 1 and 3 years. Allogeneic CLET
had a 1- and 3-year survival probability of 0.667 (CI 95%,
0.420–1.00) and 0.556 (CI 95%, 0.31–1.00), respectively. The
difference in survival between autografts and allografts was
not significant (log-rank test, 𝑝 = 0.0949).
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Figure 2: Kaplan-Meier survival (success) curves of the 20 cases undergoing cultivated limbal epithelial transplantation (CLET) according to
follow-up time (maximum of 36 months) (a) and separated by the origin of cells, allogeneic CLET (b) and autologous CLET (c). Shaded areas
represent the confidence bands. Survival analysis showed a probability of success at 1-2 years and at 3 years after CLET of 0.80 (confidence
interval [CI] 95%, 0.643–0.996) and 0.75 (CI 95%, 0.582–0.966), respectively, for all cases (a). Allogeneic CLET had a 1-2-year and a 3-year
survival probability of 0.667 (CI 95%, 0.420–1) and 0.556 (CI 95%, 0.31–1), respectively (b). The survival probability for autologous CLET
was 0.9091 (CI 95%, 0.0867–0.7541) after 1, 2, or 3 years (c). The difference in survival between autografts and allografts was not significant
(log-rank test, 𝑝 value: 0.0949).
3.2. Clinical Outcome
3.2.1. Quality of Life andOcular Surface Symptoms. TheOSDI
score for ocular surface symptoms at the initial evaluationwas
49.5± 25.8 (Table 1), indicating that the symptomswere severe
[30]. All cases showed a reduction in OSDI score following
the first month after CLET (36.1 ± 25.2; Wilcoxon signed-
rank test, 𝑝 = 0.001). The improvement was maintained
one year after CLET (34.3 ± 23.4, Wilcoxon signed-rank test,
𝑝 = 0.0035; Table 1). The scores were not influenced by the
source of donor cells (autologous versus allogeneic) (𝑡-test,
initial visit 𝑝 = 0.0954, final visit 𝑝 = 0.1420).
The visual-related quality of life score after CLET, mea-
sured by the NEI-VFQ-25, improved from 64.7 ± 22.9 at
the initial evaluation to 71.5 ± 19.4 at the 1-year follow-up
(Wilcoxon signed-rank test, 𝑝 = 0.0057, Table 1).
Autograft cases started with significantly higher NEI-
VFQ-25 values than allografts at the initial visit (76.9 ± 9.2
versus 49.8 ± 26.1, resp., 𝑡-test, 𝑝 = 0.0147). The autograft
cases also endedwith significantly higher scores than the allo-
graft cases at the final visit (81.5 ± 9.4 versus 59.3 ± 22.0, resp.,
𝑡-test, 𝑝 = 0.0176). However, when the increased percent of
NEI-VFQ-25 score afterCLETwas compared for the two graft
procedures, the difference between autografts and allografts
was not significant (16.0 ± 20.0% versus 18.6 ± 26.0%, resp.;
Mann-Whitney 𝑈 test, 𝑝 = 0.8788). Therefore, it is not
possible to say that autografts improved visual-related quality
of life issues more than allografts did.
3.2.2. Parameters Evaluated by SLE. By SLE, complete reab-
sorption of the amniotic membrane was observed at 4 weeks
after surgery in 12 eyes (60%), between 5 and 7weeks in 7 eyes
(35%), and in 8 weeks in one eye (5%).
Hyperemiawas one of the signs that patients verbalized as
having improved the most. It went from 3.0 ± 1.0 (median ±
IQR) at the initial evaluation to 1.0 ± 1.3 at month 12
(Wilcoxon signed-rank test, 𝑝 = 0.0001), improving in all 20
eyes (Table 1). At the initial visit, hyperemia was significantly
greater (Mann-Whitney 𝑈 test, 𝑝 = 0.0170) in those patients
that would later have allogeneic CLET, 3.0 ± 1.0, versus those
who would receive an autograft, 2.0 ± 1.5.
The preoperative central corneal epithelial opacity score
was 3.0 ± 1.3 (median ± IQR), and it improved significantly
to 2.0 ± 1.3 (Wilcoxon signed-rank test, 𝑝 = 0.0003) at one
year (Table 1). For all three failed cases, the initial opacity
score was at themaximum value of 4 and did not change after
CLET (Table 1). It also remained unchanged in the partial
success case (Case 16). For the remaining 16 eyes, central
corneal epithelial opacity scores decreased. Considering only
successful cases at the end of the 12 month follow-up,
corneal central opacity was significantly greater in cases with
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Figure 3: Case 17 (Table 1) before and after cultivated limbal epithelial transplantation (CLET). This 52-year-old male suffered a chemical
injury in his right eye 5 years earlier. He developed total limbal stem cell deficiency and showed at the initial visit an opaque and
vascularized cornea (a) with a conjunctival-like phenotype at in vivo confocal microscopy (IVCM) in central cornea (star), with goblet cells
(horizontal arrow), inflammatory cells (vertical arrow), and Langerhans cell (circle), (a1). He received an allogeneic cultivated limbal epithelial
transplantation (CLET). (b)After 12months and althoughhis symptoms and ciliary hyperemia had improved, this casewas considered aCLET
failure as his epithelial phenotype in central cornea (b1) was still conjunctival-like (star), with inflammatory cells (vertical arrow), evaluated
by IVCM.
autografts, 2.0 ± 1.0, compared to those with allografts (0.5 ±
1.0, Mann-Whitney 𝑈 test, 𝑝 = 0.0479).
Epithelial irregularity in the central cornea was signif-
icantly reduced from the initial score of 3.0 ± 1.0 to 1.0 ±
1.0 at the 12-month follow-up visit (Wilcoxon signed-rank
test, 𝑝 = 0.0002). For 17 of 20 eyes (85%), it decreased by a
single step. For one eye, Case 13, it decreased by two steps.
For the 3 cases that failed, the epithelial irregularity remained
at the maximum pre-CLET level (Table 1). These results were
independent of the source of cells (autologous or allogeneic)
(Mann-Whitney 𝑈 test, initial visit 𝑝 = 0.2321, final visit
𝑝 = 0.7419).
Superficial punctate keratitis, measured by corneal flu-
orescein staining, had a median pre-CLET score of 3.00 ±
1.25 that diminished at 12 months after CLET to 0.5 ± 1.0
(Wilcoxon signed-rank test, 𝑝 = 0.0010). It increased in 2 of
the 3 failed cases at 12 months and remained the same in the
other failure and in the partially successful case. It was one of
the parameters that improved in all successful cases, except
for Case 13, where it was unchanged, as there was no initial
corneal fluorescein staining (Table 1).
In the 12-month follow-up visit, corneal fluorescein stain-
ing was greater in those eyes that had received allografts,
1.0 ± 1.0, compared to those with autografts, 0.0 ± 0.5
(Mann-Whitney 𝑈 test, 𝑝 value = 0.0288). Considering only
successful cases, there was tendency for greater staining in
eyes that had received allografts compared to eyes that had
received autografts, but the difference was not significant
(Mann-Whitney 𝑈 test, 𝑝 value = 0.0814).
In agreement with the corneal staining, persistent epithe-
lial defects also improved significantly (Wilcoxon signed-
rank test, 𝑝 = 0.0115). It was present in 8 cases before CLET
and improved to total closure in successful cases. None of
the failed cases had preoperative epithelial defects, however
(Table 1). The source of cells, autografts versus allografts, did
not affect this parameter (Mann-Whitney 𝑈 test, initial visit
𝑝 = 0.8965, at the final visit all cases equal 0).
Corneal neovascularization decreased in area from 3.5
± 1.3 at the pre-CLET assessment to 2.0 ± 2.0 after 12
months (Wilcoxon signed-rank test, 𝑝 = 0.0009) (Table 1).
Similarly, the length decreased from 3.0 ± 2.0 to 2.0 ± 1.3
at the 12-month follow-up (Wilcoxon signed-rank test, 𝑝 =
0.0043). For the three failed cases (Figure 3) and for the
partially successful case, the values remained unchanged at
12 months from the initial high values. It also remained
unchanged in Case 5 that failed at 35 months after CLET.
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Figure 4: Case 8 (Table 1) before and after cultivated limbal epithelial transplantation (CLET). This 36-year-old man had limbal stem cell
deficiency due to a unilateral chemical burn, with vascular pannus invading the visual axis (a). (a1) In vivo confocalmicroscopy (IVCM) shows
a typical conjunctival-like epithelial phenotype in his central cornea (star), with goblet cells (arrow) and fibrosis (black arrowhead).This case
was graded preoperatively in terms of visual prognosis as Grade 1, meaning that only cultivated epithelial transplantation (CLET) would
be required for visual rehabilitation. After 12 months, this case was considered successful as all clinical signs improved (b) and symptoms
decreased and IVCM showed an epithelial corneal phenotype (b1).
Case 20, although successful, had mild neovascularization
that remained unchanged in area but increased one step
regarding neovessel length (Table 1). Corneal neovessel scores
were unaffected by the nature of the cells (auto- or allogeneic)
transplanted (Mann-Whitney 𝑈 test, initial visit neovessel
area 𝑝 = 0.7427 and neovessel length, 𝑝 = 0.66; final visit
neovessel area 𝑝 = 0.4589 and neovessel length 𝑝 = 0.8099).
3.3. IVCM Determination of Epithelial Phenotypes in the
Central Cornea. Evaluation of the central corneal epithelial
cell phenotypes by laser IVCM was the most objective
primary endpoint [24, 33]. Before CLET, 13 eyes (65%; Cases
3, 4, 8, 9–17, and 20) had a conjunctival epithelial phenotype in
the central cornea (Figures 3–5). One year after CLET, 6 of the
13 cases (Cases 3, 8–10, 13, and 20) improved to the corneal-
like epithelium phenotype (Figure 4), and 5 eyes (Cases 4,
11, 12, 14, and 15) evolved to a mixed phenotype (Figure 5).
The partially successful case (Case 17) and one of the 3 failed
cases (Case 17) maintained the conjunctival phenotype. The
remaining 7 eyes (Cases 1, 2, 5–7, 18, and 19) were classified
in the initial examination as having the mixed epithelium
phenotype. One year after CLET, 5 of these eyes (71.43%)
changed to the corneal phenotype (Cases 2, 5–7, and 19).The 2
remaining cases (Cases 1 and 18) worsened to the conjunctival
phenotype and were consequently considered failures. The
type of transplant, autograft or allograft, had no influence in
these results (Fisher’s exact test, initial visit 𝑝 = 0.6424, final
visit 𝑝 = 0.3359).
In summary, at the end of the first year after CLET, 80% of
the cases had improved epithelial status in the central cornea.
Of these cases, 68.8% improved from conjunctival to corneal
phenotype. Of the total number of cases, the epithelial status
of 10% remained unchanged and 10% worsened.
3.4. BCVA, Visual Potential, and Visual Rehabilitation. In
successful cases, BCVA increased from 0.15 ± 0.24 at the
initial visit to 0.25 ± 0.33 at 12 months after CLET (Wilcoxon
signed-rank test, 𝑝 = 0.0059). However, when all cases were
analyzed, the increase in BCVA, from 0.15 ± 0.25 initially
to 0.20 ± 0.25 at 12 months, was not significant (Wilcoxon
signed-rank test, 𝑝 = 0.0914). These results were not affected
by the source of donor cells (autologous or allogeneic CLET)
(Mann-Whitney test, initial visit 𝑝 = 0.1779, final visit 𝑝 =
0.2022).
In 10 successful cases at one year after CLET (Cases 5,
8–10, 12–15, 19, and 20), BCVA improved one line or more
(Table 1).These cases represented 50% of the total 20 eyes and
62.5% of the 16 successful eyes. These 16 eyes were the only
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Figure 5: Case 11 (Table 1) before and after cultivated limbal epithelial transplantation (CLET).This 27-year-old male had a total limbal stem
cell deficiency due to an early failed penetrating keratoplasty 7 years before. It was performed 5 years after a contact lens-relatedAcanthamoeba
keratitis (a). (a1) In vivo confocalmicroscopy (IVCM) in the central cornea showed intense fibrosis (black arrows) and a conjunctival epithelial
phenotype. (a2) Limbal cells for cultivated limbal epithelial transplantation (CLET) were obtained from his contralateral healthy eye, the
biopsy site ofwhich is shown 3months after biopsy. (b) Twelvemonths after autologousCLET, corneal neovascularization had almost vanished
and IVCM showed a mixed epithelium phenotype (b1), conjunctival phenotype (star), and corneal phenotype (square). (b2) Limbal donor
site 12 months after biopsy. (c) Fourteen months after CLET, a penetrating keratoplasty and cataract removal were performed, followed 12
months later with a compact and clear graft. IVCM showed a corneal phenotype (c1). (c2) The corneal transplant was still successful after
2 years (3 years after CLET) although an Ahmed valve was implanted 10 months after corneal transplant to treat his elevated intraocular
pressure.
ones with any probability to improve (Table 2, prognostic
Grade 1, 2, 3, or 4). The visual prognosis was Grade 0 in
the remaining 4 eyes for which the retinal pathology was
irreversible. Five of the 10 cases (Cases 5, 8, 9, 10, and 20) were
previously assigned a visual prognosis of Grade 1, meaning
that CLET alone, without further intervention, was likely
to improve vision (Table 2, Figure 4). Two more of those
10 eyes (Cases 12 and 13) were assigned Grade 3, meaning
that a corneal transplant would be needed. Unexpectedly,
they improved sufficiently to refuse any further rehabilitation.
The predictions in Cases 11 (Figure 5) and 14, Grade 4, were
accurate. Case 14 required a full thickness corneal transplant
and cataract removal. Although the patient was very satisfied
with the result, only a modest gain in BCVA was achieved.
This patient had been warned in advance about the potential
for a poor visual result regardless of any rehabilitation. She
had undergone three previous surgeries due to retinal detach-
ment, and the affected eye had 45-degree exotropia before
CLET. Case 15 decided not to have any further rehabilitation
as he had gained comfort, and due to moderate to severe
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nystagmus, it was unlikely that his vision would improve.The
visual potential prediction in Case 19 was also adequate with
an improved BCVA of 0.2 with a mild nystagmus.
BCVA remained unchanged in 8 cases (Cases 2–4, 6, 7,
11, 16, and 17; 40% of the total 20 eyes and 37.5% of the 16
successful eyes). Four of the successful eyes (Cases 2, 3, 4, and
7) were given a visual potential of Grade 0, as all of themwere
previously affected by irreversible retinal pathologies. Thus
no change in BCVA was expected. The central cornea status
of successful Case 6 (visual potential Grade 1) improved, but
his already goodBCVAdidnot improve,whichwas attributed
to cataract progression. In one more successful eye (Case 11,
Figure 5), as predicted based on the assigned visual potential
of Grade 4, BCVA only improved from hand motion to 0.4
after corneal transplantation and cataract removal. Partially
successful Case 16 had a predicted visual potential of Grade
3, and he refused to pursue a corneal transplant because of
the improved comfort after CLET and the full vision with his
fellow eye. Case 17 (Figure 3), with a predicted visual potential
of Grade 4, failed, and no further action was considered.
Vision became further impaired in 2 of the 3 cases (Cases
1 and 18) considered as failures. This represents 10% of the
total 20 eyes. In Case 18, BCVA diminished dramatically, not
because her corneal status became further impaired (Table 1),
but rather due to intense progression in her incipient cataract.
The rapid development of the cataract could have been due
to the large amount of steroids that she needed, because in
addition to eyedrops, she also required both inhaled and
oral steroids for her severe asthma.This patient subsequently
enrolled in the ocular surface cell therapy clinical trial
previously mentioned.
4. Discussion
With this study, we have added to the existing body of data
that supports the safety and efficacy of CLET procedures
performed under GMP rules for the management of ocular
surface failure due to LSCD. Overall, our major findings are
that (1) 80% of the cases were successful at 1 and 2 years
after transplantation and 75% remained successful at 3 years,
(2) the efficacies of autologous and allogeneic limbal cell
culture were similar to one another, and (3) among the three
prognostic groups, those with chemical burns had the least
satisfactory outcomes.
We also showed the feasibility of mild immunosuppres-
sion for a year.There were no adverse effects and no episodes
of immune rejection [26]. Whether or not immunosuppres-
sion is absolutely necessary is yet controversial due to the
reported immunoprotective properties of limbal stem cells
against inflammatory challenges of the ocular surface [3, 22].
This study also clarifies the need for strict and well-
predefined success criteria, which has been stressed by almost
all authors working in this field. We adopted a modified
combination of the criteria used by Shortt et al. [24]. These
or a different arrangement of evaluation outcomes should be
agreed upon so that studies from different parts of the world
could be more comparable and so that multicenter studies
and clinical trials could be a reality [34].
The intention of CLET is to improve the damaged or
diseased corneal epithelium phenotype and integrity and
subsequently to improve corneal barrier function. In support
of that goal, this study also confirms laser IVCM as an
excellent minimally invasive imaging technique to visualize
with great detail the quality of the corneal epithelium before
and after CLET. Although it may not be necessary in routine
clinic evaluations, it proved to be a powerful tool in the
evaluation of the corneal epithelium in our study and in
clinical trials where objective endpoints are required [24, 33].
Since the first two patients undergoing successful autolo-
gous CLET for unilateral chemical burns in 1997 [21], many
more reports have been published using this transplantation
technique. Not surprisingly, these reports have utilized differ-
ent sets of patients, cell product preparation protocols, surgi-
cal techniques, evaluation criteria endpoints, and follow-up
periods.There aremany relevant reviews focused on different
aspects of corneal stem cell transplantation that are beyond
the scope of this publication, which focusesmainly on clinical
reports. In general, CLET success rates are above 60% as
reviewed by Baylis et al. in 2013 [6] and earlier by Shortt et
al. in 2007 [35].
Our study can be better compared to those performed, as
ours was, after the EU Tissues and Cells Directive and GMP
rules becamemandatory in the EU in 2006. In our series of 20
cases, the success ratewas 80%at both 1 and 2 years and 75%at
3 years. Nevertheless, the obvious differences in patients and
protocols prevent full and totally reliable comparisons among
different studies.
The first study published in Europe in compliance with
European regulations and GMP rules was by Shortt et al.
in 2008 [24] (Moorfields Eye Hospital-University College
of London, London, United Kingdom). They reported 10
cases with 6-month success of 60%, evaluated clinically by
corneal impression cytology and by IVCM. They had the
same proportion of chemically injured eyes, 40%, as our
series, with no cases of immune-based cicatrizing ocular
surface diseases. In contrast, 20% of our cases were immune-
based cicatrizing diseases.Their series, as ours, included both
autograft and allogeneic CLET cases. Although no statistical
analyses were done, these authors reported better results for
allografts (70%, 7 of 10 cases) than for autografts (33%, 3 of 10
eyes).We had a slightly better prognosis for autografts but the
difference in outcomes between autografts and allografts was
not statistically significant.The fact that their allograft tissues
derived from donor cadavers were larger than the autologous
tissue might have influenced their results. In contrast, we
used the same amount of tissue for each type of transplant.
However, it is difficult to say if the amount of tissue starting
for the in vitro expansion could have a significant effect on the
outcome. Vision improved in 70% of Shortt et al.’s, 10 patients,
whereas it did so in 50% of our patients. In the subset of
our cases that were considered successful, 62.5% of the eyes
showed vision improvement.
Preparation of the cell product by Shortt et al. [24] was
similar to ours. They also used amniotic membrane but
prepared the limbal cells in a suspension culture system,while
we used an explant culture system.We have ample experience
in both techniques and are now considering changing to
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the cell suspension technique. Currently in our laboratory,
cell suspensions achievemore confluent primary cell cultures,
in less time, with more cells and with less fibroblast contami-
nation, although both techniques have the same cell viability
and proliferative capacity and same electron microscopy
characteristics (unpublished data).These results, however, are
derived from expanded cadaveric tissues sent for research
purposes and thus are not suitable for clinical uses. The
tissues were from very old donors (around 80 years old) and
had longer elapsed times between enucleation and culture
(data not shown). It is possible that the differences between
cell suspension- and explant-derived cells will not be the
same with the cadaveric tissues used for clinical purposes.
Cadaveric tissues suitable for clinical applications are always
derived from donors who are younger in age (less than 60
years old in our series) and for which there is less time
between enucleation and usage. These factors are reported
to be influential in clinical outcomes [36]. In contrast to
cadaveric tissues, autologous tissues are always fresher (pro-
cessedwithin 4 hr. in our cases) and not available for research.
Shimazaki et al. compared the explant technique without the
use of feeder cells or air lifting to the explant techniques with
3T3 feeder cells and airlifting and with the cell suspension
technique [37]. They found similar in vitro characteristics
among the culture techniques, but the clinical results were
best with cells derived by suspension culture, in agreement
with other authors [21, 25]. This is one of the many aspects
that needs careful evaluation in future well-designed studies.
The surgical technique and medical management used
by Shortt et al. [24] were quite similar to ours, although
they placed their cell product with cells facing externally,
while we did just the opposite. These authors also relied
on IVCM as the primary objective measure of success, and
in fact we followed their parameters. We decided not to
perform impression cytology, because in agreement with
other authors [25, 38], it is painful, unnecessary, and risky.
Impression cytology requires stripping off 3-4 layers of
corneal epithelium, a procedure that unnecessarily stresses
the new, healthier tissue. Further, impression cytology does
not add any relevant information to the clinical diagnosis
[38]. IVCM is better and more safely serves as an objective
method to evaluate the corneal epithelium [24, 33]. In any
case, neither IVCM nor other more invasive procedures are
necessary to establish the success or failure of CLET in the
routine clinical environment.
Shortt et al. recently reported the 3-year results on LSCD
for Stevens-Johnson syndrome and congenital aniridia [34],
diseases that we have classified in prognostic Groups 2 and
3, respectively. They found positive results at one year and
a deterioration of the tissues thereafter. Our two congenital
aniridia cases and two of the three Stevens-Johnson cases,
however, remained stable. The third Stevens-Johnson case
failed at 34 months. Immune-based cicatrizing disorders are
very difficult to treat, and they have a poor prognosis [37].
Although most authors have claimed stability after one year,
this is not yet fully known, especially with respect to the
different etiologies. There are no published large case series
on these nonchemical burn eyes as they are rare diseases.
Our results will need corroboration as it would be very useful
to know how the duration of CLET success depends on the
etiology of each disease.
Two years after the first European study by Shortt et al.
[24] that followed the institution of GMP regulations, Kolli
et al. [39] (Royal Victoria Infirmary-Newcastle Univer-
sity, Newcastle Upon Tyne, United Kingdom) attempted to
attribute the success or failure of treating LSCD with CLET
solely to the cell product. They recruited a strictly uniform
group of 8 patients with unilateral total LSCDdue to chemical
burns. They treated the cases by autologous CLET, using
amniotic membrane and xeno-free products under GMP
rules. Based on clinical evaluation, they reported a 100%
success rate with a mean follow-up of 19 months. Vision
improved in 5 of the 8 eyes, a success rate similar to our own
(62.5%). In our study, we had only 4 chemical burn cases
treated with autologous CLET (Cases 1, 8, 13, and 20, Table 2),
which were the most comparable with Kolli et al. [39]. While
one case failed, vision improved in the other 3 cases.
Using fibrin-cultured autologous CLET, Rama et al. [25]
reported on 107 cases followed up for a mean of about 3
years.Their success rate was 68.2% after one graft, with a final
successful clinical outcome of 76.6% after regrafting 11 eyes.
This success rate is very similar to ours, 75% at 3 years, even
though most of their cases were chemical/thermal injuries
and they only performed autografts. Full evaluations were
done at 1 year, as we did, and grafts that were considered
successful remained stable. Failed cases did not worsen as
compared with baseline, as we also observed.Their judgment
for success/failure was based on clinical grounds, and like us,
they stopped doing corneal impression cytology for the same
reasons that we did not do them.
The main difference with our protocol and that of Rama
et al. is the stem cell final product.They used a fibrin-derived
matrix instead of amniotic membrane like we used. Addi-
tionally, Rama et al. used clinical grade-certified 3T3-J2 cells,
a mouse embryonic 3T3 fibroblast cell line that was lethally
irradiated, as a feeder layer in contrast to our use of denuded
amniotic membrane. In contrast to our use of the explant
technique and the subsequent outgrowth of primary cell
cultures, they used primary cell cultures that were trypsinized
to transfer the cells to the fibrin-based substrate. Additionally,
their cell cultures were transplanted 24–36 hr. after transfer to
the transport container while ours were used within the next
4 hr. In summary, different etiologies, different cell sources
(always autologous for Rama et al.), and different cell product
protocols prevent reliable comparisons. Nevertheless, despite
all the significant differences, our final success rates were
fairly similar. This perhaps indicates that different protocols
may work equally well as long as viable, stem cell-like cells
are transplanted, as they showed in their series. How all of the
possible variables affect the final outcome remains unknown,
and it would be extremely difficult to test each of the variables
independently. Thus we advocate reaching an agreement on
all possible variables in all centers willing to participate in
multicenter studies.
In 2010, Pauklin et al. [40] (University of Duisburg-Essen,
Essen, Germany) published a series of LSCD cases for 32
total CLET eyes and 12 partial ones. The mean follow-up
time was approximately 2 years, and their success rate, based
16 BioMed Research International
on clinical grounds, was similar to ours, between 68% (full
corneal stability) and 84% (clear central cornea). Graftingwas
significantly more successful in eyes treated with autologous
CLET (77% of 30 eyes) than with allogeneic CLET (50% of 14
eyes, cadaveric or living related donors), in disagreementwith
our results and others [24, 41]. Perhaps the better prognosis
of the etiologies undergoing autologous CLET could explain
their better results.While they did not state that they adhered
to the GMP standards, their cell product was fairly similar
to ours, although they used intact amniotic membrane while
we used denuded membranes. It seems as though they must
have applied the cells facing externally because they placed
a second amniotic membrane as a patch. Interestingly, they
provoked a pharmacological eyelid ptosis to protect the graft,
while we used a large contact lens.
In 2011, Sangwan and his group [42] (L. V. Prasad Eye
Institute, Hyderabad, India) published a 10-year (2001–2010)
retrospective study on xeno-free autologous CLET, includ-
ing the largest series reported, 200 unilateral total LSCD
cases due to chemical burns. Their cell product, prepared
without clear reference to GMP adherence, was a limbal
cell monolayer on denuded amniotic membrane, as ours;
however, they did not plate the whole explant, but rather,
shredded it first to obtain primary cultures. They reported
71% success rate, evaluated on clinical grounds, with a mean
follow-up of 3 years, very similar to our series and as reported
by most authors. Failures occurred mainly within the first
year. They also reported a visual gain of two lines in 60.5%
of eyes with no further surgery, similar to our 50–62.5%
with visual gain. They used sutures or fibrin glue and did
concomitant symblepharon surgery in 45% of cases and
keratoplasty in 5% of them. Although understandable in
clinical practice, performingmore than one surgery certainly
increases postoperative inflammation, and that can affect lim-
bal cell survival. In fact, the same group later reported a worse
prognosis when penetrating keratoplasty was performed at
the same time as autologousCLET thanwhenCLETwas done
first and keratoplasty at least 6 weeks after [43]. We waited a
year to schedule our two penetrating keratoplasty cases, as
did most authors, including Basu et al., who later waited at
least one year after CLET before the next surgery [44]. We
strongly recommend avoiding any surgery other than CLET
in the context of prospective clinical studies and trials so as
not to mask results from CLET.
These authors also reported similar results with autol-
ogous CLET irrespective of whether the limbal biopsy was
taken from a healthy section of the affected eye or from
the contralateral eye [45]. Several groups have reported that
CLET can be safely repeated [25, 42, 46, 47].We repeated one
case in our series that ended up as partial success (Case 16),
but with great alleviation of symptoms.
Sejpal et al. [47] also have significant experience in
CLET for pediatric patients, mostly due to chemical/thermal
injuries. The success rates for these cases were similar to
those reported for adults. Similarly good results for pediatric
CLET in 26 ocular burn cases were reported by Vajpayee et
al. [48]. We had no pediatric cases, as the main cause for
LSCD in children, chemical injuries, is exceedingly rare in our
geographic area.
Prabhasawat et al. [41] (Siriraj Hospital-Mahidol Uni-
versity, Bangkok, Thailand) published a series of 19 LSCD
cases (13 total, 6 partial) managed with CLET. Whether or
not GMP rules were followed was not stated. They used
clinical observations and impression cytology to evaluate
success/failure, and their series had etiologies similar to
ours. They reported final success of 73.7% with a mean
follow-up of 26 months, although they included some cases
followed up for only 6 months. They used limbal sections
ranging from 2 × 2mm to 2 × 2 cm from contralateral eyes.
The epithelium was detached from the limbal explants with
dispase and seeded on amniotic membrane with a final yield
of 2–4 layers of epithelium. This suggests that limbal cells
may have been differentiated as what happens when stem
cells become multilayered [49]. In two cases at the time of
surgery, a 6-mmcentral disk was punched out of the amniotic
membrane upon which the cells were cultured, which would
have eliminated a significant number of transplanted cells.
They also removed symblepharon in some patients at the
same time of grafting, even using mitomycin C, which is
unusual and can mask results. They stated that the autografts
were less successful (66.7%, 8 of 12) than the allografts (85.7%,
6 of 7). These results were similar to Shortt et al. [24] but
contrary to Paulkin et al. [40] and us. Perhaps the fact that
83.3% of their autografts and 42.9% of their allografts were
for chemical burns could explain this difference. Additionally,
they had more symblepharon cases within the eyes that had
received autografts. While the final success rate was similar
to ours, differences in surgical management and cell products
make comparisons difficult.
In 2013, Qi et al. [26] (Shandong Eye Institute, Qingdao,
China) published, without any statement on GMP policy, a
series of 42 eyes undergoing allogeneic CLET. They centered
their work on the incidence of immune rejection, describing
the clinical characteristics. They reported 23.8% immune
rejections, all in eyes with chemical/thermal burns and
occurring between 1 and 6 months. The outcome for the
remaining 32 eyes (76.2%) was successful. This success rate
was similar to ours, although our failures were not immune
rejection-related, probably because our patients had systemic
immunosuppression. This immune rejection rate cannot be
taken as the rate under nonmedicated circumstances, as their
patients received high, immunosuppressive doses of systemic
steroids. They also had frequent use of topical steroids and
1% cyclosporine eyedrops. We, as others, strongly prefer
using oral nonsteroidal immunosuppression rather than high
doses of oral steroids that can produce a high frequency of
undesirable and severe side effects.
The most recent series reported in the EU was in 2014 by
Zakaria et al. [38] (Antwerp University Hospital, Antwerp,
Belgium) in which 15 patients had total and 3 had partial
LSCD, with etiologies similar to ours. Autologous (𝑛 = 15)
or allogeneic (𝑛 = 3, 2 from HLA-matched living related
donors and 1 from cadaveric donor) xeno-free CLET was
performed and followed up for 22 months. The clinically
judged overall success rate was 67%, worse in chemical burns
but similar to our 75% at 3 years. Contrary to our results,
these authors did not see a significant reduction in pain or
photophobia. This could be due to the great difficulty in
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properly assessing clinical symptoms in patients and/or the
fact that they used clinical scales for pain and photophobia
to measure symptoms, while we used the OSDI and NEI-VF-
25 assessments. They cultivated explants on top of amniotic
membranes and followed the same technique as ours to
prepare the host bed. However, they applied the composite
graft, for example, amniotic membrane and cells facing up,
with tissue fibrin glue. They then placed a second amniotic
membrane on top and tucked it under the conjunctiva before
suturing it. A big difference is that, at the time of surgery,
the composite graft contained both the cultured cells and the
original limbal biopsy, which we removed when outgrowth
was seen.They do not state if they operated under GMP rules,
although they probably did as it is mandatory in the EU.They
started offering corneal transplantation one year post-op, as
we did. We also agree with these authors in not performing
corneal impression cytology because the cell pick-up was
low and the procedure risked disrupting the transplanted
epithelium.
5. Conclusion
In conclusion, we showed that limbal cell expansion and
culture can be successfully achieved following our protocol
using GMP conditions and following EU regulations. Both
autologous and allogeneic CLET significantly improved the
quality of corneal epithelium in patients with ocular surface
failure due to LSCD. It enabled subsequent improvement in
symptoms, increasing the quality of life in 75% of the patients
after 3 years. These results confirm other reports that CLET
is a successful treatment for ocular surface failure due to
LSCD, although in some patients it seems to be insufficient.
The merits of having a predefined prognostic schema like
ours (Table 2) or one similar to it seem self-evident. It
provides documentable guidelines for different surgical and
medical treatments and sets reasonable physician and patient
expectations for outcomes based on the current status of the
eye. Thus we encourage the routine use of it or ones like it.
In our study, visual improvement was achieved in those eyes
previously classified in our schema as having the potential to
gain visionwith only CLET. Symptomswere greatly alleviated
in all successful patients. Our study also affirms that laser
IVCM is a good, minimally invasive, technique to assess the
main evaluation endpoint, corneal epithelium restoration in
the central cornea, in clinical studies and trials. Finally, we
demonstrated that a strict but ample clinical composite score
coupled with an objective imaging technique is ideal tool for
use in future clinical trials.
Finally, consensus in cell preparation protocols and
patient-related issues (pre-, intra-, and postoperative) should
be sought to coordinate multicenter clinical studies and trials
that help answer many of the still remaining questions about
this otherwise overall successful transplantation technique.
Needless to say, clinical efforts must be paralleled with
research efforts so that these complex and difficult blinding
diseases can be better treated.
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